5va2 › Citations

Cryo-EM Structure of the Open Human Ether-à-go-go-Related K+ Channel hERG.

Wang W, MacKinnon R
Cell 169 422-430.e10 (2017)
Related entries: 5va1, 5va3

Cited: 270 times
EuropePMC logo PMID: 28431243

Abstract

The human ether-à-go-go-related potassium channel (hERG, Kv11.1) is a voltage-dependent channel known for its role in repolarizing the cardiac action potential. hERG alteration by mutation or pharmacological inhibition produces Long QT syndrome and the lethal cardiac arrhythmia torsade de pointes. We have determined the molecular structure of hERG to 3.8 Å using cryo-electron microscopy. In this structure, the voltage sensors adopt a depolarized conformation, and the pore is open. The central cavity has an atypically small central volume surrounded by four deep hydrophobic pockets, which may explain hERG's unusual sensitivity to many drugs. A subtle structural feature of the hERG selectivity filter might correlate with its fast inactivation rate, which is key to hERG's role in cardiac action potential repolarization.

Reviews - 5va2 mentioned but not cited (9)

  1. An Update on the Structure of hERG. Butler A, Helliwell MV, Zhang Y, Hancox JC, Dempsey CE. Front Pharmacol 10 1572 (2019)
  2. New Structures and Gating of Voltage-Dependent Potassium (Kv) Channels and Their Relatives: A Multi-Domain and Dynamic Question. Barros F, Pardo LA, Domínguez P, Sierra LM, de la Peña P. Int J Mol Sci 20 E248 (2019)
  3. The EAG Voltage-Dependent K+ Channel Subfamily: Similarities and Differences in Structural Organization and Gating. Barros F, de la Peña P, Domínguez P, Sierra LM, Pardo LA. Front Pharmacol 11 411 (2020)
  4. Structures Illuminate Cardiac Ion Channel Functions in Health and in Long QT Syndrome. Brewer KR, Kuenze G, Vanoye CG, George AL, Meiler J, Sanders CR. Front Pharmacol 11 550 (2020)
  5. Gating and regulation of KCNH (ERG, EAG, and ELK) channels by intracellular domains. Codding SJ, Johnson AA, Trudeau MC. Channels (Austin) 14 294-309 (2020)
  6. P-Loop Channels: Experimental Structures, and Physics-Based and Neural Networks-Based Models. Tikhonov DB, Zhorov BS. Membranes (Basel) 12 229 (2022)
  7. Recent advances in our understanding of the structure and function of more unusual cation channels. Brown BM, Nguyen HM, Wulff H. F1000Res 8 F1000 Faculty Rev-123 (2019)
  8. Pro-arrhythmic effects of gain-of-function potassium channel mutations in the short QT syndrome. Hancox JC, Du CY, Butler A, Zhang Y, Dempsey CE, Harmer SC, Zhang H. Philos Trans R Soc Lond B Biol Sci 378 20220165 (2023)
  9. Molecular Insights Into the Gating Kinetics of the Cardiac hERG Channel, Illuminated by Structure and Molecular Dynamics. Zequn Z, Jiangfang L. Front Pharmacol 12 687007 (2021)

Articles - 5va2 mentioned but not cited (42)

  1. Cryo-EM Structure of the Open Human Ether-à-go-go-Related K+ Channel hERG. Wang W, MacKinnon R. Cell 169 422-430.e10 (2017)
  2. Gating mechanism of Kv11.1 (hERG) K+ channels without covalent connection between voltage sensor and pore domains. de la Peña P, Domínguez P, Barros F. Pflugers Arch 470 517-536 (2018)
  3. Determinants of Isoform-Specific Gating Kinetics of hERG1 Channel: Combined Experimental and Simulation Study. Perissinotti LL, De Biase PM, Guo J, Yang PC, Lee MC, Clancy CE, Duff HJ, Noskov SY. Front Physiol 9 207 (2018)
  4. Selectivity filter modalities and rapid inactivation of the hERG1 channel. Miranda WE, DeMarco KR, Guo J, Duff HJ, Vorobyov I, Clancy CE, Noskov SY. Proc Natl Acad Sci U S A 117 2795-2804 (2020)
  5. Development of a High-Throughput Flow Cytometry Assay to Monitor Defective Trafficking and Rescue of Long QT2 Mutant hERG Channels. Kanner SA, Jain A, Colecraft HM. Front Physiol 9 397 (2018)
  6. Mechanism of C-type inactivation in the hERG potassium channel. Li J, Shen R, Reddy B, Perozo E, Roux B. Sci Adv 7 eabd6203 (2021)
  7. The hERG potassium channel intrinsic ligand regulates N- and C-terminal interactions and channel closure. Codding SJ, Trudeau MC. J Gen Physiol 151 478-488 (2019)
  8. Calculation of absolute binding free energies between the hERG channel and structurally diverse drugs. Negami T, Araki M, Okuno Y, Terada T. Sci Rep 9 16586 (2019)
  9. The Pore-Lipid Interface: Role of Amino-Acid Determinants of Lipophilic Access by Ivabradine to the hERG1 Pore Domain. Perissinotti L, Guo J, Kudaibergenova M, Lees-Miller J, Ol'khovich M, Sharapova A, Perlovich GL, Muruve DA, Gerull B, Noskov SY, Duff HJ. Mol Pharmacol 96 259-271 (2019)
  10. Regulation of Eag1 gating by its intracellular domains. Whicher JR, MacKinnon R. Elife 8 e49188 (2019)
  11. Assessing hERG1 Blockade from Bayesian Machine-Learning-Optimized Site Identification by Ligand Competitive Saturation Simulations. Mousaei M, Kudaibergenova M, MacKerell AD, Noskov S. J Chem Inf Model 60 6489-6501 (2020)
  12. Functional characterization of Kv11.1 (hERG) potassium channels split in the voltage-sensing domain. de la Peña P, Domínguez P, Barros F. Pflugers Arch 470 1069-1085 (2018)
  13. Allosteric Coupling Between Drug Binding and the Aromatic Cassette in the Pore Domain of the hERG1 Channel: Implications for a State-Dependent Blockade. Kudaibergenova M, Guo J, Khan HM, Zahid F, Lees-Miller J, Noskov SY, Duff HJ. Front Pharmacol 11 914 (2020)
  14. Revealing the efficacy-toxicity relationship of Fuzi in treating rheumatoid arthritis by systems pharmacology. Feng W, Liu J, Zhang D, Tan Y, Cheng H, Peng C. Sci Rep 11 23083 (2021)
  15. Toward Reducing hERG Affinities for DAT Inhibitors with a Combined Machine Learning and Molecular Modeling Approach. Lee KH, Fant AD, Guo J, Guan A, Jung J, Kudaibergenova M, Miranda WE, Ku T, Cao J, Wacker S, Duff HJ, Newman AH, Noskov SY, Shi L. J Chem Inf Model 61 4266-4279 (2021)
  16. Inhibition of the hERG potassium channel by phenanthrene: a polycyclic aromatic hydrocarbon pollutant. Al-Moubarak E, Shiels HA, Zhang Y, Du C, Hanington O, Harmer SC, Dempsey CE, Hancox JC. Cell Mol Life Sci 78 7899-7914 (2021)
  17. Molecular dynamics simulations suggest possible activation and deactivation pathways in the hERG channel. Costa F, Guardiani C, Giacomello A. Commun Biol 5 165 (2022)
  18. Refinement of a cryo-EM structure of hERG: Bridging structure and function. Khan HM, Guo J, Duff HJ, Tieleman DP, Noskov SY. Biophys J 120 738-748 (2021)
  19. Structural modeling of the hERG potassium channel and associated drug interactions. Maly J, Emigh AM, DeMarco KR, Furutani K, Sack JT, Clancy CE, Vorobyov I, Yarov-Yarovoy V. Front Pharmacol 13 966463 (2022)
  20. A standardised hERG phenotyping pipeline to evaluate KCNH2 genetic variant pathogenicity. Oliveira-Mendes B, Feliciangeli S, Ménard M, Chatelain F, Alameh M, Montnach J, Nicolas S, Ollivier B, Barc J, Baró I, Schott JJ, Probst V, Kyndt F, Denjoy I, Lesage F, Loussouarn G, De Waard M. Clin Transl Med 11 e609 (2021)
  21. Electrophysiological and Proarrhythmic Effects of Hydroxychloroquine Challenge in Guinea-Pig Hearts. Wang G, Lu CJ, Trafford AW, Tian X, Flores HM, Maj P, Zhang K, Niu Y, Wang L, Du Y, Ji X, Xu Y, Wu L, Li D, Herring N, Paterson D, Huang CL, Zhang H, Lei M, Hao G. ACS Pharmacol Transl Sci 4 1639-1653 (2021)
  22. Lipid regulation of hERG1 channel function. Miranda WE, Guo J, Mesa-Galloso H, Corradi V, Lees-Miller JP, Tieleman DP, Duff HJ, Noskov SY. Nat Commun 12 1409 (2021)
  23. Molecular determinants of pro-arrhythmia proclivity of d- and l-sotalol via a multi-scale modeling pipeline. DeMarco KR, Yang PC, Singh V, Furutani K, Dawson JRD, Jeng MT, Fettinger JC, Bekker S, Ngo VA, Noskov SY, Yarov-Yarovoy V, Sack JT, Wulff H, Clancy CE, Vorobyov I. J Mol Cell Cardiol 158 163-177 (2021)
  24. Noncanonical electromechanical coupling paths in cardiac hERG potassium channel. Bassetto CAZ, Costa F, Guardiani C, Bezanilla F, Giacomello A. Nat Commun 14 1110 (2023)
  25. Selection of safe artemisinin derivatives using a machine learning-based cardiotoxicity platform and in vitro and in vivo validation. Kadioglu O, Klauck SM, Fleischer E, Shan L, Efferth T. Arch Toxicol 95 2485-2495 (2021)
  26. Toward in vivo-relevant hERG safety assessment and mitigation strategies based on relationships between non-equilibrium blocker binding, three-dimensional channel-blocker interactions, dynamic occupancy, dynamic exposure, and cellular arrhythmia. Wan H, Selvaggio G, Pearlstein RA. PLoS One 15 e0234946 (2020)
  27. In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel-A Drug Antitarget. Al-Moubarak E, Sharifi M, Hancox JC. Front Cardiovasc Med 8 645172 (2021)
  28. Antiepileptic Drug Tiagabine Does Not Directly Target Key Cardiac Ion Channels Kv11.1, Nav1.5 and Cav1.2. Kowalska M, Fijałkowski Ł, Kubacka M, Sałat K, Grześk G, Nowaczyk J, Nowaczyk A. Molecules 26 3522 (2021)
  29. Early Steps in C-Type Inactivation of the hERG Potassium Channel. Pettini F, Domene C, Furini S. J Chem Inf Model 63 251-258 (2023)
  30. Exploiting ion channel structure to assess rare variant pathogenicity. Kroncke BM, Yang T, Kannankeril P, Shoemaker MB, Roden DM. Heart Rhythm 15 890-894 (2018)
  31. Mechanism of hERG inhibition by gating-modifier toxin, APETx1, deduced by functional characterization. Matsumura K, Shimomura T, Kubo Y, Oka T, Kobayashi N, Imai S, Yanase N, Akimoto M, Fukuda M, Yokogawa M, Ikeda K, Kurita JI, Nishimura Y, Shimada I, Osawa M. BMC Mol Cell Biol 22 3 (2021)
  32. Non-canonical helical transitions and conformational switching are associated with characteristic flexibility and disorder indices in TRP and Kv channels. García-Morales A, Balleza D. Channels (Austin) 17 2212349 (2023)
  33. The cellular pathways that maintain the quality control and transport of diverse potassium channels. Nguyen NH, Brodsky JL. Biochim Biophys Acta Gene Regul Mech 1866 194908 (2023)
  34. Voltage vs. Ligand II: Structural insights of the intrinsic flexibility in cyclic nucleotide-gated channels. Romero-Romero S, Martínez-Delgado G, Balleza D. Channels (Austin) 13 382-399 (2019)
  35. Investigation of PAS and CNBH domain interactions in hERG channels and effects of long-QT syndrome-causing mutations with surface plasmon resonance. Soohoo SM, Tiwari PB, Suzuki YJ, Brelidze TI. J Biol Chem 298 101433 (2022)
  36. N- and C-terminal interactions in KCNH channels: The spotlight on the intrinsic ligand. Brelidze TI. J Gen Physiol 151 400-403 (2019)
  37. Use of Solvent Mapping for Characterizing the Binding Site and for Predicting the Inhibition of the Human Ether-á-Go-Go-Related K+ Channel. Ma S, Sun Z, Jing Y, McGann M, Vajda S, Enyedy IJ. Chem Res Toxicol 35 1359-1369 (2022)
  38. Evolutionary coupling analysis guides identification of mistrafficking-sensitive variants in cardiac K+ channels: Validation with hERG. Zhang Y, Grimwood AL, Hancox JC, Harmer SC, Dempsey CE. Front Pharmacol 13 1010119 (2022)
  39. research-article Harnessing AlphaFold to reveal state secrets: Prediction of hERG closed and inactivated states. Ngo K, Yarov-Yarovoy V, Clancy CE, Vorobyov I. bioRxiv 2024.01.27.577468 (2024)
  40. research-article Photo-crosslinking hERG channels causes a U.V.-driven, state-dependent disruption of kinetics and voltage dependence of activation. Codding SJ, Trudeau MC. bioRxiv 2024.01.09.574834 (2024)
  41. Structural modeling of hERG channel-drug interactions using Rosetta. Emigh Cortez AM, DeMarco KR, Furutani K, Bekker S, Sack JT, Wulff H, Clancy CE, Vorobyov I, Yarov-Yarovoy V. Front Pharmacol 14 1244166 (2023)
  42. The voltage-sensing domain of a hERG1 mutant is a cation-selective channel. Kudaibergenova M, Guo J, Khan HM, Lees-Miller J, Mousaei M, Miranda W, Ngo VA, Noskov SY, Tieleman DP, Duff HJ. Biophys J 121 4585-4599 (2022)


Reviews citing this publication (66)

  1. Cryo-EM in drug discovery: achievements, limitations and prospects. Renaud JP, Chari A, Ciferri C, Liu WT, Rémigy HW, Stark H, Wiesmann C. Nat Rev Drug Discov 17 471-492 (2018)
  2. Antibodies and venom peptides: new modalities for ion channels. Wulff H, Christophersen P, Colussi P, Chandy KG, Yarov-Yarovoy V. Nat Rev Drug Discov 18 339-357 (2019)
  3. Membrane protein structural biology in the era of single particle cryo-EM. Cheng Y. Curr Opin Struct Biol 52 58-63 (2018)
  4. Structural insights into the mechanisms of CNBD channel function. James ZM, Zagotta WN. J Gen Physiol 150 225-244 (2018)
  5. Towards a Structural View of Drug Binding to hERG K+ Channels. Vandenberg JI, Perozo E, Allen TW. Trends Pharmacol Sci 38 899-907 (2017)
  6. Calcium channel gating. Hering S, Zangerl-Plessl EM, Beyl S, Hohaus A, Andranovits S, Timin EN. Pflugers Arch 470 1291-1309 (2018)
  7. Ether-à-go-go K+ channels: effective modulators of neuronal excitability. Bauer CK, Schwarz JR. J Physiol 596 769-783 (2018)
  8. Venom-derived peptide inhibitors of voltage-gated potassium channels. Norton RS, Chandy KG. Neuropharmacology 127 124-138 (2017)
  9. Evolution and Structural Characteristics of Plant Voltage-Gated K+ Channels. Jegla T, Busey G, Assmann SM. Plant Cell 30 2898-2909 (2018)
  10. Voltage-Sensing Phosphatases: Biophysics, Physiology, and Molecular Engineering. Okamura Y, Kawanabe A, Kawai T. Physiol Rev 98 2097-2131 (2018)
  11. Cryo-EM as a powerful tool for drug discovery. Van Drie JH, Tong L. Bioorg Med Chem Lett 30 127524 (2020)
  12. Ion channels as lipid sensors: from structures to mechanisms. Thompson MJ, Baenziger JE. Nat Chem Biol 16 1331-1342 (2020)
  13. Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned. Choi R, Hulverson MA, Huang W, Vidadala RSR, Whitman GR, Barrett LK, Schaefer DA, Betzer DP, Riggs MW, Doggett JS, Hemphill A, Ortega-Mora LM, McCloskey MC, Arnold SLM, Hackman RC, Marsh KC, Lynch JJ, Freiberg GM, Leroy BE, Kempf DJ, Choy RKM, de Hostos EL, Maly DJ, Fan E, Ojo KK, Van Voorhis WC. Int J Parasitol 50 413-422 (2020)
  14. Long QT Syndrome Type 2: Emerging Strategies for Correcting Class 2 KCNH2 (hERG) Mutations and Identifying New Patients. Ono M, Burgess DE, Schroder EA, Elayi CS, Anderson CL, January CT, Sun B, Immadisetty K, Kekenes-Huskey PM, Delisle BP. Biomolecules 10 E1144 (2020)
  15. A current understanding of drug-induced QT prolongation and its implications for anticancer therapy. Roden DM. Cardiovasc Res 115 895-903 (2019)
  16. Challenges and advances in atomistic simulations of potassium and sodium ion channel gating and permeation. DeMarco KR, Bekker S, Vorobyov I. J Physiol 597 679-698 (2019)
  17. Impact of the Protein Data Bank on antineoplastic approvals. Westbrook JD, Soskind R, Hudson BP, Burley SK. Drug Discov Today 25 837-850 (2020)
  18. Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. Zequn Z, Yujia W, Dingding Q, Jiangfang L. Eur J Pharmacol 893 173813 (2021)
  19. Applications of In-Cell NMR in Structural Biology and Drug Discovery. Kang C. Int J Mol Sci 20 E139 (2019)
  20. Computational chemical biology and drug design: Facilitating protein structure, function, and modulation studies. Zheng M, Zhao J, Cui C, Fu Z, Li X, Liu X, Ding X, Tan X, Li F, Luo X, Chen K, Jiang H. Med Res Rev 38 914-950 (2018)
  21. Impact of structural biologists and the Protein Data Bank on small-molecule drug discovery and development. Burley SK. J Biol Chem 296 100559 (2021)
  22. CNG channel structure, function, and gating: a tale of conformational flexibility. Napolitano LMR, Torre V, Marchesi A. Pflugers Arch 473 1423-1435 (2021)
  23. Structural Insights into the Mechanisms and Pharmacology of K2P Potassium Channels. Natale AM, Deal PE, Minor DL. J Mol Biol 433 166995 (2021)
  24. Discovery of KV 1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges. Gubič Š, Hendrickx LA, Toplak Ž, Sterle M, Peigneur S, Tomašič T, Pardo LA, Tytgat J, Zega A, Mašič LP. Med Res Rev 41 2423-2473 (2021)
  25. Modulation of hERG K+ Channel Deactivation by Voltage Sensor Relaxation. Shi YP, Thouta S, Claydon TW. Front Pharmacol 11 139 (2020)
  26. Never at rest: insights into the conformational dynamics of ion channels from cryo-electron microscopy. Lau C, Hunter MJ, Stewart A, Perozo E, Vandenberg JI. J Physiol 596 1107-1119 (2018)
  27. Genetic and Molecular Aspects of Drug-Induced QT Interval Prolongation. Baracaldo-Santamaría D, Llinás-Caballero K, Corso-Ramirez JM, Restrepo CM, Dominguez-Dominguez CA, Fonseca-Mendoza DJ, Calderon-Ospina CA. Int J Mol Sci 22 8090 (2021)
  28. Protein structure and computational drug discovery. Nero TL, Parker MW, Morton CJ. Biochem Soc Trans 46 1367-1379 (2018)
  29. hERG Function in Light of Structure. Robertson GA, Morais-Cabral JH. Biophys J 118 790-797 (2020)
  30. Cholesterol-Dependent Gating Effects on Ion Channels. Jiang QX. Adv Exp Med Biol 1115 167-190 (2019)
  31. Diverse Structural Features of Potassium Channels Characterized by Scorpion Toxins as Molecular Probes. Zhao Y, Chen Z, Cao Z, Li W, Wu Y. Molecules 24 E2045 (2019)
  32. Hydrophobic Drug/Toxin Binding Sites in Voltage-Dependent K+ and Na+ Channels. Van Theemsche KM, Van de Sande DV, Snyders DJ, Labro AJ. Front Pharmacol 11 735 (2020)
  33. In Vitro and In Silico Risk Assessment in Acquired Long QT Syndrome: The Devil Is in the Details. Lee W, Windley MJ, Vandenberg JI, Hill AP. Front Physiol 8 934 (2017)
  34. Atomistic Insights of Calmodulin Gating of Complete Ion Channels. Núñez E, Muguruza-Montero A, Villarroel A. Int J Mol Sci 21 E1285 (2020)
  35. KV11.1, NaV1.5, and CaV1.2 Transporter Proteins as Antitarget for Drug Cardiotoxicity. Kowalska M, Nowaczyk J, Nowaczyk A. Int J Mol Sci 21 E8099 (2020)
  36. Mapping Electromechanical Coupling Pathways in Voltage-Gated Ion Channels: Challenges and the Way Forward. Cowgill J, Chanda B. J Mol Biol 433 167104 (2021)
  37. Noncanonical Ion Channel Behaviour in Pain. Ciotu CI, Tsantoulas C, Meents J, Lampert A, McMahon SB, Ludwig A, Fischer MJM. Int J Mol Sci 20 E4572 (2019)
  38. Kv Channel Ancillary Subunits: Where Do We Go from Here? Abbott GW. Physiology (Bethesda) 37 0 (2022)
  39. Membranes under the Magnetic Lens: A Dive into the Diverse World of Membrane Protein Structures Using Cryo-EM. Piper SJ, Johnson RM, Wootten D, Sexton PM. Chem Rev 122 13989-14017 (2022)
  40. cyclic AMP Regulation and Its Command in the Pacemaker Channel HCN4. Porro A, Thiel G, Moroni A, Saponaro A. Front Physiol 11 771 (2020)
  41. How to Connect Cardiac Excitation to the Atomic Interactions of Ion Channels. Silva JR. Biophys J 114 259-266 (2018)
  42. Machine Learning Toxicity Prediction: Latest Advances by Toxicity End Point. Cavasotto CN, Scardino V. ACS Omega 7 47536-47546 (2022)
  43. Molecular mechanisms of coupling to voltage sensors in voltage-evoked cellular signals. Okamura Y, Okochi Y. Proc Jpn Acad Ser B Phys Biol Sci 95 111-135 (2019)
  44. Peptide Toxins Targeting KV Channels. Matsumura K, Yokogawa M, Osawa M. Handb Exp Pharmacol 267 481-505 (2021)
  45. The bare necessities of plant K+ channel regulation. Lefoulon C. Plant Physiol 187 2092-2109 (2021)
  46. Ventricular voltage-gated ion channels: Detection, characteristics, mechanisms, and drug safety evaluation. Chen L, He Y, Wang X, Ge J, Li H. Clin Transl Med 11 e530 (2021)
  47. Fenestropathy of Voltage-Gated Sodium Channels. Gamal El-Din TM, Lenaeus MJ. Front Pharmacol 13 842645 (2022)
  48. Genetics of congenital arrhythmia syndromes: the challenge of variant interpretation. Glazer AM. Curr Opin Genet Dev 77 102004 (2022)
  49. Mechanisms Underlying C-type Inactivation in Kv Channels: Lessons From Structures of Human Kv1.3 and Fly Shaker-IR Channels. Ong ST, Tyagi A, Chandy KG, Bhushan S. Front Pharmacol 13 924289 (2022)
  50. Mutation-Specific Differences in Kv7.1 (KCNQ1) and Kv11.1 (KCNH2) Channel Dysfunction and Long QT Syndrome Phenotypes. Kekenes-Huskey PM, Burgess DE, Sun B, Bartos DC, Rozmus ER, Anderson CL, January CT, Eckhardt LL, Delisle BP. Int J Mol Sci 23 7389 (2022)
  51. Pharmacological activation of the hERG K+ channel for the management of the long QT syndrome: A review. El Harchi A, Brincourt O. J Arrhythm 38 554-569 (2022)
  52. The ERG1 K+ Channel and Its Role in Neuronal Health and Disease. Sanchez-Conde FG, Jimenez-Vazquez EN, Auerbach DS, Jones DK. Front Mol Neurosci 15 890368 (2022)
  53. Cardiac K+ Channels and Channelopathies. Schreiber JA, Seebohm G. Handb Exp Pharmacol 267 113-138 (2021)
  54. Electron microscopy of cardiac 3D nanodynamics: form, function, future. Kohl P, Greiner J, Rog-Zielinska EA. Nat Rev Cardiol 19 607-619 (2022)
  55. In Silico Models for Predicting Acute Systemic Toxicity. Tsakovska I, Diukendjieva A, Worth AP. Methods Mol Biol 2425 259-289 (2022)
  56. Simulation and Machine Learning Methods for Ion-Channel Structure Determination, Mechanistic Studies and Drug Design. Zhu Z, Deng Z, Wang Q, Wang Y, Zhang D, Xu R, Guo L, Wen H. Front Pharmacol 13 939555 (2022)
  57. The genetics of drug-induced QT prolongation: evaluating the evidence for pharmacodynamic variants. Lopez-Medina AI, Chahal CAA, Luzum JA. Pharmacogenomics 23 543-557 (2022)
  58. Ca2+- and Voltage-Activated K+ (BK) Channels in the Nervous System: One Gene, a Myriad of Physiological Functions. Ancatén-González C, Segura I, Alvarado-Sánchez R, Chávez AE, Latorre R. Int J Mol Sci 24 3407 (2023)
  59. Fifty years of gating currents and channel gating. Catacuzzeno L, Conti F, Franciolini F. J Gen Physiol 155 e202313380 (2023)
  60. Molecular dynamics: a powerful tool for studying the medicinal chemistry of ion channel modulators. Şterbuleac D. RSC Med Chem 12 1503-1518 (2021)
  61. Recent Advances in Computer-Aided Structure-Based Drug Design on Ion Channels. Pliushcheuskaya P, Künze G. Int J Mol Sci 24 9226 (2023)
  62. Structure of the voltage-gated potassium channel KV1.3: Insights into the inactivated conformation and binding to therapeutic leads. Chandy KG, Sanches K, Norton RS. Channels (Austin) 17 2253104 (2023)
  63. [Progress on structural biology of voltage-gated ion channels]. Song F, Guo J. Zhejiang Da Xue Xue Bao Yi Xue Ban 48 25-33 (2019)
  64. A need for exhaustive and standardized characterization of ion channels activity. The case of KV11.1. Alameh M, Oliveira-Mendes BR, Kyndt F, Rivron J, Denjoy I, Lesage F, Schott JJ, De Waard M, Loussouarn G. Front Physiol 14 1132533 (2023)
  65. Facilitation of hERG Activation by Its Blocker: A Mechanism to Reduce Drug-Induced Proarrhythmic Risk. Furutani K. Int J Mol Sci 24 16261 (2023)
  66. Structural Plasticity of the Selectivity Filter in Cation Channels. Hendriks K, Öster C, Lange A. Front Physiol 12 792958 (2021)

Articles citing this publication (153)

  1. Human In Silico Drug Trials Demonstrate Higher Accuracy than Animal Models in Predicting Clinical Pro-Arrhythmic Cardiotoxicity. Passini E, Britton OJ, Lu HR, Rohrbacher J, Hermans AN, Gallacher DJ, Greig RJH, Bueno-Orovio A, Rodriguez B. Front Physiol 8 668 (2017)
  2. Activation mechanism of a human SK-calmodulin channel complex elucidated by cryo-EM structures. Lee CH, MacKinnon R. Science 360 508-513 (2018)
  3. The gating cycle of a K+ channel at atomic resolution. Cuello LG, Cortes DM, Perozo E. Elife 6 e28032 (2017)
  4. Voltage Sensor Movements during Hyperpolarization in the HCN Channel. Lee CH, MacKinnon R. Cell 179 1582-1589.e7 (2019)
  5. Guidelines for using Bsoft for high resolution reconstruction and validation of biomolecular structures from electron micrographs. Heymann JB. Protein Sci 27 159-171 (2018)
  6. Single-particle cryo-EM structure of a voltage-activated potassium channel in lipid nanodiscs. Matthies D, Bae C, Toombes GE, Fox T, Bartesaghi A, Subramaniam S, Swartz KJ. Elife 7 e37558 (2018)
  7. A pharmacological master key mechanism that unlocks the selectivity filter gate in K+ channels. Schewe M, Sun H, Mert Ü, Mackenzie A, Pike ACW, Schulz F, Constantin C, Vowinkel KS, Conrad LJ, Kiper AK, Gonzalez W, Musinszki M, Tegtmeier M, Pryde DC, Belabed H, Nazare M, de Groot BL, Decher N, Fakler B, Carpenter EP, Tucker SJ, Baukrowitz T. Science 363 875-880 (2019)
  8. Crystal structure of an inactivated mutant mammalian voltage-gated K+ channel. Pau V, Zhou Y, Ramu Y, Xu Y, Lu Z. Nat Struct Mol Biol 24 857-865 (2017)
  9. Molecular mechanism of a potassium channel gating through activation gate-selectivity filter coupling. Kopec W, Rothberg BS, de Groot BL. Nat Commun 10 5366 (2019)
  10. Shifts in the selectivity filter dynamics cause modal gating in K+ channels. Jekhmane S, Medeiros-Silva J, Li J, Kümmerer F, Müller-Hermes C, Baldus M, Roux B, Weingarth M. Nat Commun 10 123 (2019)
  11. Gating interaction maps reveal a noncanonical electromechanical coupling mode in the Shaker K+ channel. Fernández-Mariño AI, Harpole TJ, Oelstrom K, Delemotte L, Chanda B. Nat Struct Mol Biol 25 320-326 (2018)
  12. Helix breaking transition in the S4 of HCN channel is critical for hyperpolarization-dependent gating. Kasimova MA, Tewari D, Cowgill JB, Ursuleaz WC, Lin JL, Delemotte L, Chanda B. Elife 8 e53400 (2019)
  13. K2P channel C-type gating involves asymmetric selectivity filter order-disorder transitions. Lolicato M, Natale AM, Abderemane-Ali F, Crottès D, Capponi S, Duman R, Wagner A, Rosenberg JM, Grabe M, Minor DL. Sci Adv 6 eabc9174 (2020)
  14. Electromechanical coupling in the hyperpolarization-activated K+ channel KAT1. Clark MD, Contreras GF, Shen R, Perozo E. Nature 583 145-149 (2020)
  15. Insights into the molecular mechanism for hyperpolarization-dependent activation of HCN channels. Flynn GE, Zagotta WN. Proc Natl Acad Sci U S A 115 E8086-E8095 (2018)
  16. A Computational Pipeline to Predict Cardiotoxicity: From the Atom to the Rhythm. Yang PC, DeMarco KR, Aghasafari P, Jeng MT, Dawson JRD, Bekker S, Noskov SY, Yarov-Yarovoy V, Vorobyov I, Clancy CE. Circ Res 126 947-964 (2020)
  17. Gating movements and ion permeation in HCN4 pacemaker channels. Saponaro A, Bauer D, Giese MH, Swuec P, Porro A, Gasparri F, Sharifzadeh AS, Chaves-Sanjuan A, Alberio L, Parisi G, Cerutti G, Clarke OB, Hamacher K, Colecraft HM, Mancia F, Hendrickson WA, Siegelbaum SA, DiFrancesco D, Bolognesi M, Thiel G, Santoro B, Moroni A. Mol Cell 81 2929-2943.e6 (2021)
  18. S4-S5 linker movement during activation and inactivation in voltage-gated K+ channels. Kalstrup T, Blunck R. Proc Natl Acad Sci U S A 115 E6751-E6759 (2018)
  19. Structural implications of hERG K+ channel block by a high-affinity minimally structured blocker. Helliwell MV, Zhang Y, El Harchi A, Du C, Hancox JC, Dempsey CE. J Biol Chem 293 7040-7057 (2018)
  20. High-throughput discovery of trafficking-deficient variants in the cardiac potassium channel KV11.1. Kozek KA, Glazer AM, Ng CA, Blackwell D, Egly CL, Vanags LR, Blair M, Mitchell D, Matreyek KA, Fowler DM, Knollmann BC, Vandenberg JI, Roden DM, Kroncke BM. Heart Rhythm 17 2180-2189 (2020)
  21. Global alignment and assessment of TRP channel transmembrane domain structures to explore functional mechanisms. Huffer KE, Aleksandrova AA, Jara-Oseguera A, Forrest LR, Swartz KJ. Elife 9 e58660 (2020)
  22. Allosteric conformational change of a cyclic nucleotide-gated ion channel revealed by DEER spectroscopy. Evans EGB, Morgan JLW, DiMaio F, Zagotta WN, Stoll S. Proc Natl Acad Sci U S A 117 10839-10847 (2020)
  23. Bipolar switching by HCN voltage sensor underlies hyperpolarization activation. Cowgill J, Klenchin VA, Alvarez-Baron C, Tewari D, Blair A, Chanda B. Proc Natl Acad Sci U S A 116 670-678 (2019)
  24. Gating mechanism of hyperpolarization-activated HCN pacemaker channels. Ramentol R, Perez ME, Larsson HP. Nat Commun 11 1419 (2020)
  25. Support Vector Machine model for hERG inhibitory activities based on the integrated hERG database using descriptor selection by NSGA-II. Ogura K, Sato T, Yuki H, Honma T. Sci Rep 9 12220 (2019)
  26. Atomistic basis of opening and conduction in mammalian inward rectifier potassium (Kir2.2) channels. Zangerl-Plessl EM, Lee SJ, Maksaev G, Bernsteiner H, Ren F, Yuan P, Stary-Weinzinger A, Nichols CG. J Gen Physiol 152 e201912422 (2020)
  27. Dynamic rearrangement of the intrinsic ligand regulates KCNH potassium channels. Dai G, James ZM, Zagotta WN. J Gen Physiol 150 625-635 (2018)
  28. Voltage-sensor movements in the Eag Kv channel under an applied electric field. Mandala VS, MacKinnon R. Proc Natl Acad Sci U S A 119 e2214151119 (2022)
  29. Experimentally Validated Pharmacoinformatics Approach to Predict hERG Inhibition Potential of New Chemical Entities. Munawar S, Windley MJ, Tse EG, Todd MH, Hill AP, Vandenberg JI, Jabeen I. Front Pharmacol 9 1035 (2018)
  30. Conformational changes upon gating of KirBac1.1 into an open-activated state revealed by solid-state NMR and functional assays. Amani R, Borcik CG, Khan NH, Versteeg DB, Yekefallah M, Do HQ, Coats HR, Wylie BJ. Proc Natl Acad Sci U S A 117 2938-2947 (2020)
  31. Potassium channel selectivity filter dynamics revealed by single-molecule FRET. Wang S, Lee SJ, Maksaev G, Fang X, Zuo C, Nichols CG. Nat Chem Biol 15 377-383 (2019)
  32. Construction of an integrated database for hERG blocking small molecules. Sato T, Yuki H, Ogura K, Honma T. PLoS One 13 e0199348 (2018)
  33. hERG1a and hERG1b potassium channel subunits directly interact and preferentially form heteromeric channels. McNally BA, Pendon ZD, Trudeau MC. J Biol Chem 292 21548-21557 (2017)
  34. Digging into Lipid Membrane Permeation for Cardiac Ion Channel Blocker d-Sotalol with All-Atom Simulations. DeMarco KR, Bekker S, Clancy CE, Noskov SY, Vorobyov I. Front Pharmacol 9 26 (2018)
  35. Mutation-specific peripheral and ER quality control of hERG channel cell-surface expression. Foo B, Barbier C, Guo K, Vasantharuban J, Lukacs GL, Shrier A. Sci Rep 9 6066 (2019)
  36. Structure-Based Prediction of hERG-Related Cardiotoxicity: A Benchmark Study. Creanza TM, Delre P, Ancona N, Lentini G, Saviano M, Mangiatordi GF. J Chem Inf Model 61 4758-4770 (2021)
  37. hiPSC-Derived Cardiomyocyte Model of LQT2 Syndrome Derived from Asymptomatic and Symptomatic Mutation Carriers Reproduces Clinical Differences in Aggregates but Not in Single Cells. Shah D, Prajapati C, Penttinen K, Cherian RM, Koivumäki JT, Alexanova A, Hyttinen J, Aalto-Setälä K. Cells 9 E1153 (2020)
  38. Asymmetry in catalysis by Thermotoga maritima membrane-bound pyrophosphatase demonstrated by a nonphosphorus allosteric inhibitor. Vidilaseris K, Kiriazis A, Turku A, Khattab A, Johansson NG, Leino TO, Kiuru PS, Boije Af Gennäs G, Meri S, Yli-Kauhaluoma J, Xhaard H, Goldman A. Sci Adv 5 eaav7574 (2019)
  39. Extracellular protons accelerate hERG channel deactivation by destabilizing voltage sensor relaxation. Shi YP, Thouta S, Cheng YM, Claydon TW. J Gen Physiol 151 231-246 (2019)
  40. Activation and closed-state inactivation mechanisms of the human voltage-gated KV4 channel complexes. Ye W, Zhao H, Dai Y, Wang Y, Lo YH, Jan LY, Lee CH. Mol Cell 82 2427-2442.e4 (2022)
  41. Research Support, Non-U.S. Gov't Binding modes of hERG blockers: an unsolved mystery in the drug design arena. Kalyaanamoorthy S, Barakat KH. Expert Opin Drug Discov 13 207-210 (2018)
  42. Discovery of a heme-binding domain in a neuronal voltage-gated potassium channel. Burton MJ, Cresser-Brown J, Thomas M, Portolano N, Basran J, Freeman SL, Kwon H, Bottrill AR, Llansola-Portoles MJ, Pascal AA, Jukes-Jones R, Chernova T, Schmid R, Davies NW, Storey NM, Dorlet P, Moody PCE, Mitcheson JS, Raven EL. J Biol Chem 295 13277-13286 (2020)
  43. Electromechanical coupling mechanism for activation and inactivation of an HCN channel. Dai G, Aman TK, DiMaio F, Zagotta WN. Nat Commun 12 2802 (2021)
  44. Molecular basis for functional connectivity between the voltage sensor and the selectivity filter gate in Shaker K+ channels. Bassetto CA, Carvalho-de-Souza JL, Bezanilla F. Elife 10 e63077 (2021)
  45. Pore-modulating toxins exploit inherent slow inactivation to block K+ channels. Karbat I, Altman-Gueta H, Fine S, Szanto T, Hamer-Rogotner S, Dym O, Frolow F, Gordon D, Panyi G, Gurevitz M, Reuveny E. Proc Natl Acad Sci U S A 116 18700-18709 (2019)
  46. Blockade of the Human Ether A-Go-Go-Related Gene (hERG) Potassium Channel by Fentanyl. Tschirhart JN, Li W, Guo J, Zhang S. Mol Pharmacol 95 386-397 (2019)
  47. Cryo-EM structure of the KvAP channel reveals a non-domain-swapped voltage sensor topology. Tao X, MacKinnon R. Elife 8 e52164 (2019)
  48. Inactivation in the potassium channel KcsA. Xu Y, McDermott AE. J Struct Biol X 3 100009 (2019)
  49. Opening TRPP2 (PKD2L1) requires the transfer of gating charges. Ng LCT, Vien TN, Yarov-Yarovoy V, DeCaen PG. Proc Natl Acad Sci U S A 116 15540-15549 (2019)
  50. Potent hERG channel inhibition by sarizotan, an investigative treatment for Rett Syndrome. Cheng H, Du C, Zhang Y, James AF, Dempsey CE, Abdala AP, Hancox JC. J Mol Cell Cardiol 135 22-30 (2019)
  51. Probing the molecular basis of hERG drug block with unnatural amino acids. Macdonald LC, Kim RY, Kurata HT, Fedida D. Sci Rep 8 289 (2018)
  52. The molecular determinants of R-roscovitine block of hERG channels. Cernuda B, Fernandes CT, Allam SM, Orzillo M, Suppa G, Chia Chang Z, Athanasopoulos D, Buraei Z. PLoS One 14 e0217733 (2019)
  53. Chlorpromazine binding to the PAS domains uncovers the effect of ligand modulation on EAG channel activity. Wang ZJ, Soohoo SM, Tiwari PB, Piszczek G, Brelidze TI. J Biol Chem 295 4114-4123 (2020)
  54. Rearrangement of a unique Kv1.3 selectivity filter conformation upon binding of a drug. Tyagi A, Ahmed T, Jian S, Bajaj S, Ong ST, Goay SSM, Zhao Y, Vorobyov I, Tian C, Chandy KG, Bhushan S. Proc Natl Acad Sci U S A 119 e2113536119 (2022)
  55. TMEM266 is a functional voltage sensor regulated by extracellular Zn2. Papp F, Lomash S, Szilagyi O, Babikow E, Smith J, Chang TH, Bahamonde MI, Toombes GES, Swartz KJ. Elife 8 e42372 (2019)
  56. The Study on the hERG Blocker Prediction Using Chemical Fingerprint Analysis. Choi KE, Balupuri A, Kang NS. Molecules 25 E2615 (2020)
  57. Two mutations at different positions in the CNBH domain of the hERG channel accelerate deactivation and impair the interaction with the EAG domain. Kume S, Shimomura T, Tateyama M, Kubo Y. J Physiol 596 4629-4650 (2018)
  58. Precise in vivo functional analysis of DNA variants with base editing using ACEofBASEs target prediction. Cornean A, Gierten J, Welz B, Mateo JL, Thumberger T, Wittbrodt J. Elife 11 e72124 (2022)
  59. Voltage-dependent activation in EAG channels follows a ligand-receptor rather than a mechanical-lever mechanism. Malak OA, Gluhov GS, Grizel AV, Kudryashova KS, Sokolova OS, Loussouarn G. J Biol Chem 294 6506-6521 (2019)
  60. A structure-based computational workflow to predict liability and binding modes of small molecules to hERG. Kalyaanamoorthy S, Lamothe SM, Hou X, Moon TC, Kurata HT, Houghton M, Barakat KH. Sci Rep 10 16262 (2020)
  61. Action potential clamp characterization of the S631A hERG mutation associated with short QT syndrome. Butler A, Zhang Y, Stuart AG, Dempsey CE, Hancox JC. Physiol Rep 6 e13845 (2018)
  62. Exploring the Viral Channel KcvPBCV-1 Function via Computation. Andersson AEV, Kasimova MA, Delemotte L. J Membr Biol 251 419-430 (2018)
  63. Identification of a proton sensor that regulates conductance and open time of single hERG channels. Wilson SL, Dempsey CE, Hancox JC, Marrion NV. Sci Rep 9 19825 (2019)
  64. The 70-year search for the voltage-sensing mechanism of ion channels. Catacuzzeno L, Franciolini F. J Physiol 600 3227-3247 (2022)
  65. 3D Pharmacophore-Based Discovery of Novel KV10.1 Inhibitors with Antiproliferative Activity. Toplak Ž, Hendrickx LA, Gubič Š, Možina Š, Žegura B, Štern A, Novak M, Shi X, Peigneur S, Tytgat J, Tomašič T, Pardo LA, Mašič LP. Cancers (Basel) 13 1244 (2021)
  66. Conservation and variability of the pore-lining helices in P-loop channels. Tikhonov DB, Zhorov BS. Channels (Austin) 11 660-672 (2017)
  67. Dimeric structures of quinol-dependent nitric oxide reductases (qNORs) revealed by cryo-electron microscopy. Gopalasingam CC, Johnson RM, Chiduza GN, Tosha T, Yamamoto M, Shiro Y, Antonyuk SV, Muench SP, Hasnain SS. Sci Adv 5 eaax1803 (2019)
  68. Functional and pharmacological characterization of an S5 domain hERG mutation associated with short QT syndrome. Butler A, Zhang Y, Stuart AG, Dempsey CE, Hancox JC. Heliyon 5 e01429 (2019)
  69. Investigating the state dependence of drug binding in hERG channels using a trapped-open channel phenotype. Thouta S, Lo G, Grajauskas L, Claydon T. Sci Rep 8 4962 (2018)
  70. Molecular Docking Guided Grid-Independent Descriptor Analysis to Probe the Impact of Water Molecules on Conformational Changes of hERG Inhibitors in Drug Trapping Phenomenon. Munawar S, Vandenberg JI, Jabeen I. Int J Mol Sci 20 E3385 (2019)
  71. Multiscale modeling shows that dielectric differences make NaV channels faster than KV channels. Catacuzzeno L, Sforna L, Franciolini F, Eisenberg RS. J Gen Physiol 153 e202012706 (2021)
  72. Relative positioning of Kv11.1 (hERG) K+ channel cytoplasmic domain-located fluorescent tags toward the plasma membrane. Barros F, Domínguez P, de la Peña P. Sci Rep 8 15494 (2018)
  73. A second S4 movement opens hyperpolarization-activated HCN channels. Wu X, Ramentol R, Perez ME, Noskov SY, Larsson HP. Proc Natl Acad Sci U S A 118 e2102036118 (2021)
  74. Colombian Scorpion Centruroides margaritatus: Purification and Characterization of a Gamma Potassium Toxin with Full-Block Activity on the hERG1 Channel. Beltrán-Vidal J, Carcamo-Noriega E, Pastor N, Zamudio-Zuñiga F, Guerrero-Vargas JA, Castaño S, Possani LD, Restano-Cassulini R. Toxins (Basel) 13 407 (2021)
  75. Importance of the Choice of a Recombinant System to Produce Large Amounts of Functional Membrane Protein hERG. Vasseur L, Cens T, Wagner R, Saint N, Kugler V, Chavanieu A, Ouvry C, Dupré C, Ferry G, Boutin JA. Int J Mol Sci 20 E3181 (2019)
  76. Investigating the utility of adult zebrafish ex vivo whole hearts to pharmacologically screen hERG channel activator compounds. Hull CM, Genge CE, Hobbs Y, Rayani K, Lin E, Gunawan M, Shafaattalab S, Tibbits GF, Claydon TW. Am J Physiol Regul Integr Comp Physiol 317 R921-R931 (2019)
  77. Non-missense variants of KCNH2 show better outcomes in type 2 long QT syndrome. Aizawa T, Wada Y, Hasegawa K, Huang H, Imamura T, Gao J, Kashiwa A, Kohjitani H, Fukuyama M, Kato K, Kato ET, Hisamatsu T, Ohno S, Makiyama T, Kimura T, Horie M. Europace 25 1491-1499 (2023)
  78. Predicting critical drug concentrations and torsadogenic risk using a multiscale exposure-response simulator. Sahli Costabal F, Yao J, Sher A, Kuhl E. Prog Biophys Mol Biol 144 61-76 (2019)
  79. Rutaecarpine targets hERG channels and participates in regulating electrophysiological properties leading to ventricular arrhythmia. Zhan G, Wang F, Ding YQ, Li XH, Li YX, Zhao ZR, Li JX, Liu Y, Zhao X, Yan CC, Li BX. J Cell Mol Med 25 4938-4949 (2021)
  80. Structure of KCNH2 cyclic nucleotide-binding homology domain reveals a functionally vital salt-bridge. Ben-Bassat A, Giladi M, Haitin Y. J Gen Physiol 152 e201912505 (2020)
  81. The Fast Component of hERG Gating Charge: An Interaction between D411 in the S1 and S4 Residues. Dou Y, Macdonald LC, Wu Y, Fedida D. Biophys J 113 1979-1991 (2017)
  82. Antibodies Targeting KV Potassium Channels: A Promising Treatment for Cancer. Hernandez-Resendiz I, Hartung F, Pardo LA. Bioelectricity 1 180-187 (2019)
  83. Cardiac hERG K+ Channel as Safety and Pharmacological Target. Su S, Sun J, Wang Y, Xu Y. Handb Exp Pharmacol 267 139-166 (2021)
  84. Computational approaches to understand the adverse drug effect on potassium, sodium and calcium channels for predicting TdP cardiac arrhythmias. Sharifi M. J Mol Graph Model 76 152-160 (2017)
  85. Letter Cryo-EM structure of the hyperpolarization-activated inwardly rectifying potassium channel KAT1 from Arabidopsis. Li S, Yang F, Sun D, Zhang Y, Zhang M, Liu S, Zhou P, Shi C, Zhang L, Tian C. Cell Res 30 1049-1052 (2020)
  86. Disruption of protein quality control of the human ether-à-go-go related gene K+ channel results in profound long QT syndrome. Ledford HA, Ren L, Thai PN, Park S, Timofeyev V, Sirish P, Xu W, Emigh AM, Priest JR, Perez MV, Ashley EA, Yarov-Yarovoy V, Yamoah EN, Zhang XD, Chiamvimonvat N. Heart Rhythm 19 281-292 (2022)
  87. Estimating the Posttest Probability of Long QT Syndrome Diagnosis for Rare KCNH2 Variants. Kozek K, Wada Y, Sala L, Denjoy I, Egly C, O'Neill MJ, Aiba T, Shimizu W, Makita N, Ishikawa T, Crotti L, Spazzolini C, Kotta MC, Dagradi F, Castelletti S, Pedrazzini M, Gnecchi M, Leenhardt A, Salem JE, Ohno S, Zuo Y, Glazer AM, Mosley JD, Roden DM, Knollmann BC, Blume JD, Extramiana F, Schwartz PJ, Horie M, Kroncke BM. Circ Genom Precis Med 14 e003289 (2021)
  88. Identification of undecylenic acid as EAG channel inhibitor using surface plasmon resonance-based screen of KCNH channels. Wang ZJ, Tiwari PB, Üren A, Brelidze TI. BMC Pharmacol Toxicol 20 42 (2019)
  89. Non-sedating antihistamines block G-protein-gated inwardly rectifying K+ channels. Chen IS, Liu C, Tateyama M, Karbat I, Uesugi M, Reuveny E, Kubo Y. Br J Pharmacol 176 3161-3179 (2019)
  90. Shaker-IR K+ channel gating in heavy water: Role of structural water molecules in inactivation. Szanto TG, Gaal S, Karbat I, Varga Z, Reuveny E, Panyi G. J Gen Physiol 153 e202012742 (2021)
  91. A randomized, double-blind, crossover study of the effect of the fluoroquinolone moxifloxacin on glucose levels and insulin sensitivity in young men and women. Juhl CR, Burgdorf J, Knudsen C, Lubberding AF, Veedfald S, Isaksen JL, Hartmann B, Frikke-Schmidt R, Mandrup-Poulsen T, Holst JJ, Kanters JK, Torekov SS. Diabetes Obes Metab 25 98-109 (2023)
  92. Antimicrobial Peptides from Rat-Tailed Maggots of the Drone Fly Eristalis tenax Show Potent Activity against Multidrug-Resistant Gram-Negative Bacteria. Hirsch R, Wiesner J, Bauer A, Marker A, Vogel H, Hammann PE, Vilcinskas A. Microorganisms 8 E626 (2020)
  93. Computer Simulations Reveal a Novel Blocking Mode of the hERG Ion Channel by the Antiarrhythmic Agent Clofilium. Șterbuleac D, Maniu CL. Mol Inform 37 e1700142 (2018)
  94. Conformation-sensitive antibody reveals an altered cytosolic PAS/CNBh assembly during hERG channel gating. Harley CA, Bernardo-Seisdedos G, Stevens-Sostre WA, Jones DK, Azevedo MM, Sampaio P, Lorga-Gomes M, Trudeau MC, Millet O, Robertson GA, Morais-Cabral JH. Proc Natl Acad Sci U S A 118 e2108796118 (2021)
  95. Discovery of Novel HCN4 Blockers with Unique Blocking Kinetics and Binding Properties. Nakashima K, Nakao K, Matsui H. SLAS Discov 26 896-908 (2021)
  96. Electrophysiological characterization of the modified hERGT potassium channel used to obtain the first cryo-EM hERG structure. Zhang Y, Dempsey CE, Hancox JC. Physiol Rep 8 e14568 (2020)
  97. Molecular Basis of Altered hERG1 Channel Gating Induced by Ginsenoside Rg3. Gardner A, Wu W, Thomson S, Zangerl-Plessl EM, Stary-Weinzinger A, Sanguinetti MC. Mol Pharmacol 92 437-450 (2017)
  98. The Interaction between the Drosophila EAG Potassium Channel and the Protein Kinase CaMKII Involves an Extensive Interface at the Active Site of the Kinase. Castro-Rodrigues AF, Zhao Y, Fonseca F, Gabant G, Cadene M, Robertson GA, Morais-Cabral JH. J Mol Biol 430 5029-5049 (2018)
  99. Zinc Oxide Nanoparticles and Voltage-Gated Human Kv 11.1 Potassium Channels Interact through a Novel Mechanism. Piscopo S, Brown ER. Small 14 e1703403 (2018)
  100. A distinct mechanism of C-type inactivation in the Kv-like KcsA mutant E71V. Rohaim A, Vermeulen BJA, Li J, Kümmerer F, Napoli F, Blachowicz L, Medeiros-Silva J, Roux B, Weingarth M. Nat Commun 13 1574 (2022)
  101. A novel mutant allele of AtCNGC15 reveals a dual function of nuclear calcium release in the root meristem. Tipper E, Leitão N, Dangeville P, Lawson DM, Charpentier M. J Exp Bot 74 2572-2584 (2023)
  102. A novel mutation in KCNH2 yields loss-of-function of hERG potassium channel in long QT syndrome 2. Gu K, Qian D, Qin H, Cui C, Fernando WCHA, Wang D, Wang J, Cao K, Chen M. Pflugers Arch 473 219-229 (2021)
  103. Binding of RPR260243 at the intracellular side of the hERG1 channel pore domain slows closure of the helix bundle crossing gate. Zangerl-Plessl EM, Wu W, Sanguinetti MC, Stary-Weinzinger A. Front Mol Biosci 10 1137368 (2023)
  104. Cardiac toxicity of Triptergium wilfordii Hook F. may correlate with its inhibition to hERG channel. Zhao W, Xiao L, Pan L, Ke X, Zhang Y, Zhong D, Xu J, Cao F, Wu L, Chen Y. Heliyon 5 e02527 (2019)
  105. Computational and experimental studies on the inhibitory mechanism of hydroxychloroquine on hERG. Yu R, Li P. Toxicology 458 152822 (2021)
  106. High-Throughput Electrophysiology Screen Revealed Cardiotoxicity of Strychnine by Selectively Targeting hERG Channel. Wang T, Chen X, Yu J, Du Q, Zhu J, Yang M, Wu H, Wang M, Zhu Y. Am J Chin Med 46 1825-1840 (2018)
  107. How an intrinsic ligand tunes the activity of a potassium channel. Khoo KK, Pless SA. J Gen Physiol 150 517-520 (2018)
  108. Interplay between VSD, pore, and membrane lipids in electromechanical coupling in HCN channels. Elbahnsi A, Cowgill J, Burtscher V, Wedemann L, Zeckey L, Chanda B, Delemotte L. Elife 12 e80303 (2023)
  109. Mechanism underlying delayed rectifying in human voltage-mediated activation Eag2 channel. Zhang M, Shan Y, Pei D. Nat Commun 14 1470 (2023)
  110. New Diarylamine KV10.1 Inhibitors and Their Anticancer Potential. Gubič Š, Toplak Ž, Shi X, Dernovšek J, Hendrickx LA, Pinheiro-Junior EL, Peigneur S, Tytgat J, Pardo LA, Peterlin Mašič L, Tomašič T. Pharmaceutics 14 1963 (2022)
  111. Permeation mechanisms through the selectivity filter and the open helix bundle crossing gate of GIRK2. Li DL, Hu L, Wang L, Chen CL. Comput Struct Biotechnol J 18 3950-3958 (2020)
  112. Virtual screening of DrugBank database for hERG blockers using topological Laplacian-assisted AI models. Feng H, Wei GW. Comput Biol Med 153 106491 (2023)
  113. Voltage-Gated Potassium Channels Beyond the Action Potential. Pardo LA. Bioelectricity 4 117-125 (2022)
  114. KCNH2 encodes a nuclear-targeted polypeptide that mediates hERG1 channel gating and expression. Jain A, Stack O, Ghodrati S, Sanchez-Conde FG, Ukachukwu CU, Salwi S, Jimenez-Vazquez EN, Jones DK. Proc Natl Acad Sci U S A 120 e2214700120 (2023)
  115. Astemizole-based turn-on fluorescent probes for imaging hERG potassium channel. Zhang X, Liu T, Wang B, Gao Y, Liu P, Li M, Du L. Medchemcomm 10 513-516 (2019)
  116. Computational methods and theory for ion channel research. Guardiani C, Cecconi F, Chiodo L, Cottone G, Malgaretti P, Maragliano L, Barabash ML, Camisasca G, Ceccarelli M, Corry B, Roth R, Giacomello A, Roux B. Adv Phys X 7 2080587 (2022)
  117. Fluorescent analogues of BeKm-1 with high and specific activity against the hERG channel. Vasseur L, Chavanieu A, Combemale S, Caumes C, Béroud R, De Waard M, Ducrot P, Boutin JA, Ferry G, Cens T. Toxicon X 2 100010 (2019)
  118. Genomic, functional and structural analyses elucidate evolutionary innovation within the sea anemone 8 toxin family. Ashwood LM, Elnahriry KA, Stewart ZK, Shafee T, Naseem MU, Szanto TG, van der Burg CA, Smith HL, Surm JM, Undheim EAB, Madio B, Hamilton BR, Guo S, Wai DCC, Coyne VL, Phillips MJ, Dudley KJ, Hurwood DA, Panyi G, King GF, Pavasovic A, Norton RS, Prentis PJ. BMC Biol 21 121 (2023)
  119. High-Resolution Structures of K+ Channels. Jiang QX. Handb Exp Pharmacol 267 51-81 (2021)
  120. Histidine at position 462 determines the low quinine sensitivity of ether-à-go-go channel superfamily member Kv 12.1. Dierich M, van Ham WB, Stary-Weinzinger A, Leitner MG. Br J Pharmacol 176 2708-2723 (2019)
  121. Hysteretic hERG channel gating current recorded at physiological temperature. Jones DK. Sci Rep 12 5950 (2022)
  122. Inferring functional units in ion channel pores via relative entropy. Schmidt M, Schroeder I, Bauer D, Thiel G, Hamacher K. Eur Biophys J 50 37-57 (2021)
  123. Inhibition of the hERG Potassium Channel by a Methanesulphonate-Free E-4031 Analogue. Helliwell MV, Zhang Y, El Harchi A, Dempsey CE, Hancox JC. Pharmaceuticals (Basel) 16 1204 (2023)
  124. Integrated Approach Including Docking, MD Simulations, and Network Analysis Highlights the Action Mechanism of the Cardiac hERG Activator RPR260243. Costa F, Ocello R, Guardiani C, Giacomello A, Masetti M. J Chem Inf Model 63 4888-4899 (2023)
  125. Molecular Dynamics-Derived Pharmacophore Model Explaining the Nonselective Aspect of KV10.1 Pore Blockers. Toplak Ž, Merzel F, Pardo LA, Peterlin Mašič L, Tomašič T. Int J Mol Sci 22 8999 (2021)
  126. New Insights into Ion Channels: Predicting hERG-Drug Interactions. Wempe MF. Int J Mol Sci 23 10732 (2022)
  127. On QSAR-based cardiotoxicity modeling with the expressiveness-enhanced graph learning model and dual-threshold scheme. Wang H, Zhu G, Izu LT, Chen-Izu Y, Ono N, Altaf-Ul-Amin MD, Kanaya S, Huang M. Front Physiol 14 1156286 (2023)
  128. Probing Ion Configurations in the KcsA Selectivity Filter with Single-Isotope Labels and 2D IR Spectroscopy. Ryan MJ, Gao L, Valiyaveetil FI, Zanni MT, Kananenka AA. J Am Chem Soc 145 18529-18537 (2023)
  129. Similar voltage-sensor movement in spHCN channels can cause closing, opening, or inactivation. Wu X, Cunningham KP, Ramentol R, Perez ME, Larsson HP. J Gen Physiol 155 e202213170 (2023)
  130. Structural Modelling of KCNQ1 and KCNH2 Double Mutant Proteins, Identified in Two Severe Long QT Syndrome Cases, Reveals New Insights into Cardiac Channelopathies. Agudelo WA, Gil-Quiñones SR, Fonseca A, Arenas A, Castro L, Sierra-Díaz DC, Patarroyo MA, Laissue P, Suárez CF, Cabrera R. Int J Mol Sci 22 12861 (2021)
  131. The mutation L69P in the PAS domain of the hERG potassium channel results in LQTS by trafficking deficiency. Jenewein T, Kanner SA, Bauer D, Hertel B, Colecraft HM, Moroni A, Thiel G, Kauferstein S. Channels (Austin) 14 163-174 (2020)
  132. hERG Blockade Prediction by Combining Site Identification by Ligand Competitive Saturation and Physicochemical Properties. Goel H, Yu W, MacKerell AD. Chemistry (Basel) 4 630-646 (2022)
  133. 5-Chloro-2-Guanidinobenzimidazole (ClGBI) Is a Non-Selective Inhibitor of the Human HV1 Channel. Szanto TG, Feher A, Korpos E, Gyöngyösi A, Kállai J, Mészáros B, Ovari K, Lányi Á, Panyi G, Varga Z. Pharmaceuticals (Basel) 16 656 (2023)
  134. A new means of energy supply driven by terahertz photons recovers related neural activity. Tan X, Gao M, Chang C. iScience 26 105979 (2023)
  135. An Insight into the Potassium Currents of hERG and Their Simulation. Guidelli R. Molecules 28 3514 (2023)
  136. An LQT2-related mutation in the voltage-sensing domain is involved in switching the gating polarity of hERG. Liu Z, Wang F, Yuan H, Tian F, Yang C, Hu F, Liu Y, Tang M, Ping M, Kang C, Luo T, Yang G, Hu M, Gao Z, Li P. BMC Biol 22 29 (2024)
  137. Assembly of Cell-Free Synthesized Ion Channel Molecules in Artificial Lipid Bilayer Observed by Atomic Force Microscopy. Goh MWS, Tozawa Y, Tero R. Membranes (Basel) 13 854 (2023)
  138. Chronic Administration of COVID-19 Drugs Fluvoxamine and Lopinavir Shortens Action Potential Duration by Inhibiting the Human Ether-à-go-go-Related Gene and Cav1.2. Zheng Z, Cai D, Fu Y, Wang Y, Song Y, Lian J. Front Pharmacol 13 889713 (2022)
  139. Conformational plasticity of NaK2K and TREK2 potassium channel selectivity filters. Matamoros M, Ng XW, Brettmann JB, Piston DW, Nichols CG. Nat Commun 14 89 (2023)
  140. Letter Cryo-EM structure reveals a symmetry reduction of the plant outward-rectifier potassium channel SKOR. Li S, Wang Y, Wang C, Zhang Y, Sun D, Zhou P, Tian C, Liu S. Cell Discov 9 67 (2023)
  141. Drug-likeness of linear pentamidine analogues and their impact on the hERG K+ channel - correlation with structural features. Żołek T, Qile M, Kaźmierczak P, Bloothooft M, van der Heyden MAG, Maciejewska D. RSC Adv 9 38355-38371 (2019)
  142. External Cd2+ and protons activate the hyperpolarization-gated K+ channel KAT1 at the voltage sensor. Zhou Y, Assmann SM, Jegla T. J Gen Physiol 153 e202012647 (2021)
  143. Fluorescent membrane potential assay for drug screening on Kv10.1 channel: identification of BL-1249 as a channel activator. Gómez-Herrera MA, Patlán E, Estrada-Garrido A, Hernández-Cruz A, Luis E. Front Pharmacol 14 1238503 (2023)
  144. Molecular mechanism of EAG1 channel inhibition by imipramine binding to the PAS domain. Wang ZJ, Ghorbani M, Chen X, Tiwari PB, Klauda JB, Brelidze TI. J Biol Chem 299 105391 (2023)
  145. Multiple mechanisms underlie reduced potassium conductance in the p.T1019PfsX38 variant of hERG. Al Salmani MK, Tavakoli R, Zaman W, Al Harrasi A. Physiol Rep 10 e15341 (2022)
  146. Recombinant Production, Reconstruction in Lipid-Protein Nanodiscs, and Electron Microscopy of Full-Length α-Subunit of Human Potassium Channel Kv7.1. Shenkarev ZO, Karlova MG, Kulbatskii DS, Kirpichnikov MP, Lyukmanova EN, Sokolova OS. Biochemistry (Mosc) 83 562-573 (2018)
  147. Structure of a transporter domain emerges. Ulens C. J Biol Chem 293 20008-20009 (2018)
  148. Structure-Function Studies of Sponge-Derived Compounds on the Cardiac CaV3.1 Channel. Depuydt AS, Patel PA, Toplak Ž, Bhat C, Voráčová M, Eteläinen I, Vitulano F, Bruun T, Lempinen A, Hribernik N, Mäki-Lohiluoma E, Hendrickx L, Pinheiro-Junior EL, Tomašič T, Mašič LP, Yli-Kauhaluoma J, Kiuru P, Tytgat J, Peigneur S. Int J Mol Sci 24 3429 (2023)
  149. The N-linker region of hERG1a upregulates hERG1b potassium channels. Johnson AA, Crawford TR, Trudeau MC. J Biol Chem 298 102233 (2022)
  150. The Strength of hERG Inhibition by Erythromycin at Different Temperatures Might Be Due to Its Interacting Features with the Channels. Cheng D, Wei X, Zhang Y, Zhang Q, Xu J, Yang J, Yu J, Stalin A, Liu H, Wang J, Zhong D, Pan L, Zhao W, Chen Y. Molecules 28 5176 (2023)
  151. Utilizing Heteroatom Types and Numbers from Extensive Ligand Libraries to Develop Novel hERG Blocker QSAR Models Using Machine Learning-Based Classifiers. Haddad S, Oktay L, Erol I, Şahin K, Durdagi S. ACS Omega 8 40864-40877 (2023)
  152. Water inside the Selectivity Filter of a K+ Ion Channel: Structural Heterogeneity, Picosecond Dynamics, and Hydrogen Bonding. Ryan MJ, Gao L, Valiyaveetil FI, Kananenka AA, Zanni MT. J Am Chem Soc 146 1543-1553 (2024)
  153. hERG1 channel subunit composition mediates proton inhibition of rapid delayed rectifier potassium current (IKr) in cardiomyocytes derived from hiPSCs. Ukachukwu CU, Jimenez-Vazquez EN, Jain A, Jones DK. J Biol Chem 299 102778 (2023)


Quick links